The stock of Repligen Corp. (RGEN) has gone down by -10.66% for the week, with a 15.61% rise in the past month and a -13.73% drop in the past quarter. The volatility ratio for the week is 6.52%, and the volatility levels for the past 30 days are 5.91% for RGEN. The simple moving average for the past 20 days is -3.41% for RGEN’s stock, with a -10.70% simple moving average for the past 200 days.
Is It Worth Investing in Repligen Corp. (NASDAQ: RGEN) Right Now?
Company’s 36-month beta value is 0.95.Analysts have differing opinions on the stock, with 1 analysts rating it as a “buy,” 4 as “overweight,” 1 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for RGEN is 52.01M, and currently, short sellers hold a 8.44% ratio of that floaft. The average trading volume of RGEN on August 19, 2024 was 803.08K shares.
RGEN) stock’s latest price update
The stock of Repligen Corp. (NASDAQ: RGEN) has decreased by -9.26 when compared to last closing price of 162.61.Despite this, the company has seen a loss of -10.66% in its stock price over the last five trading days. reuters.com reported 2024-08-16 that Repligen, a provider of drug manufacturing equipment, has approached Maravai LifeSciences Holdings, a vaccine capping reagent vendor that has a market value of $2.2 billion, with an acquisition offer, people familiar with the matter said on Friday.
Analysts’ Opinion of RGEN
Many brokerage firms have already submitted their reports for RGEN stocks, with Deutsche Bank repeating the rating for RGEN by listing it as a “Buy.” The predicted price for RGEN in the upcoming period, according to Deutsche Bank is $155 based on the research report published on June 26, 2024 of the current year 2024.
RGEN Trading at 6.75% from the 50-Day Moving Average
After a stumble in the market that brought RGEN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -30.11% of loss for the given period.
Volatility was left at 5.91%, however, over the last 30 days, the volatility rate increased by 6.52%, as shares surge +19.17% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -2.09% lower at present.
During the last 5 trading sessions, RGEN fell by -10.66%, which changed the moving average for the period of 200-days by +29.24% in comparison to the 20-day moving average, which settled at $153.95. In addition, Repligen Corp. saw -17.94% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RGEN starting from KURIYEL RALF, who sale 7,148 shares at the price of $159.35 back on Aug 02 ’24. After this action, KURIYEL RALF now owns 12,288 shares of Repligen Corp., valued at $1,139,016 using the latest closing price.
Ralf Kuriyel, the Senior Vice President of Repligen Corp., proposed sale 7,148 shares at $159.35 during a trade that took place back on Aug 02 ’24, which means that Ralf Kuriyel is holding shares at $1,139,040 based on the most recent closing price.
Stock Fundamentals for RGEN
Current profitability levels for the company are sitting at:
- 0.02 for the present operating margin
- 0.41 for the gross margin
The net margin for Repligen Corp. stands at -0.0. The total capital return value is set at 0.0. Equity return is now at value -0.10, with -0.07 for asset returns.
Based on Repligen Corp. (RGEN), the company’s capital structure generated 0.23 points at debt to capital in total, while cash flow to debt ratio is standing at 0.26. The debt to equity ratio resting at 0.3. The interest coverage ratio of the stock is -3.64.
Currently, EBITDA for the company is 131.39 million with net debt to EBITDA at -2.52. When we switch over and look at the enterprise to sales, we see a ratio of 13.61. The receivables turnover for the company is 4.89for trailing twelve months and the total asset turnover is 0.21. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.65.
Conclusion
In a nutshell, Repligen Corp. (RGEN) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
